Having identified that DoG RNAs are differentially expressed and exhibit clinical significance in colon cancer, we next examined whether the Food and Drug Administration–approved TOP1 inhibitor, CPT, alters DoG RNA expression. This evidence concerns the gene TOP1 and malignant colon neoplasm.